Spy растет на премаркете

Ближайший уровень поддержки по SPY – 196.00 уровень сопротивления – 196.50



AMGN смотрим на откат вниз

WHR продажа от 150

MHK покупка выше 140

MIDD покупка выше 88

HAR покупка выше 113

SVXY покупка выше 84

GILD смотрим на продажу, ГЭП на премаркете

TAP покупка выше 75

Gapping up/down: JCP +2% after earnings, MNST +20% on KO strategic partnership, ACHN +17% after Phase 2 data; JD and JWN -4% after earnings; ICPT -2% after initiation with Underperf

Gapping up
In reaction to strong earnings/guidance: DQ +10.8%, VRML +10.7%, RIOM +9.5%, CEP +7.9%, LIME +7.6%, YOD +7.5%, SKBI +5.6%, WYY +5.4%, SINA +5.2%, ADSK +4.4%, HTM +4.3%, AMAT +3.8%, XON +3.6%, AGRX +2.7%, ROX +2.7%, CHL +2.7%, UPIP +2.5%, LEI +2%, JCP +2%, KITE +1.7%, MNDL +1.4%, AEG +1.2%, SAND +1%, EL +0.8%, A +0.7%.

M&A news: MNST +20.3% (Monster Beverage and Coca-Cola enter into long-term strategic partnership), KO +1.8% (Monster Beverage and Coca-Cola enter into long-term strategic partnership).


Other news: ACHN +17.5% (achieves 100% sustained virologic response rate from an eight week Phase 2 trial evaluating a ribavirin-free regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV), CRMD +8.2% (FDA accepted co's pivotal Phase 3 study protocol), FRO +4.3% (cont strength), SODA +3.7% (following MNST / KO ), GCI +2.3% (Icahn disclosed 6.63% active stake in 13D filing; supports split of the company), BHP +2.2% (announced update on portfolio; demerger of a selection of assets is co's preferred option), GLF +2% (to replace QCOR in the S&P SmallCap 600), DNOW +1.9% (new Berkshire Hathaway stake), PARR +1.9% (announced successful completion of common stock rights offering and award of $164 mln contract with Defense Logistics Agency Energy), MNK +1.9% (completes acquisition of Questcor (QCOR)), GILD +1.5% (disclosed favorable ruling in Roche (RHHBY) / Pharmasset case), CHTR +1% (new Berkshire Hathaway stake), EBAY +0.5% (may soon accept bitcoins at its payment unit, according to reports).

Analyst comments: CHL +2.7% (upgraded to Neutral from Underperform at Mizuho), UPL +1.8% (upgraded to Buy from Neutral at UBS ), GSJK +1.5% (upgraded to Overweight from Neutral at JP Morgan), MBI +1.2% (upgraded to Buy from Neutral at BTIG Research ), NXPI +0.8% (initiated with a Buy at Stifel)

Gapping down
In reaction to disappointing earnings/guidance: ICLD -9%, OPXA -7.8%, PIH -5.7%, PCTY -4.6%, JD -4.4%, JWN -4%, XGTI -3.9%, WB -3.1%, EXTR -1.9%.

Other news: NQ -15.8% ( announces management changes; CFO has resigned from his position for family reasons effective Aug 22, 2014), IDCC -6.7% (co announced it is disappointed with decision by the U.S. International Trade Commission to terminate Investigation No. 337-TA-868), NWBO -5.1% (announced pricing of $17.5 mln offering of convertible notes; convertible at $7.30/share; will fund new manufacturing capacity in Europe), CNAT -3.3% ( filed for a $150 mln mixed securities shelf offering), NEO -2.7% (announced public offering of common stock; size not disclosed), MASI -1.7% (disclosed it received a warning letter from the U.S. FDA regarding compliance with current Good Manufacturing Practices at Masimo's Irvine, CA manufacturing facility.), ZGNX -1.5% (disclosed it received a paragraph IV certification from Actavis (ACT) advising of the filing of an ANDA for a generic version of Zohydro).

Analyst comments: ICPT -2.1% (initiated with a Underperform at FBR Capital; tgt $172 ), KKR -1% (downgraded to Market Perform from Outperform at Wells Fargo), BEBE -0.7% (downgraded to Neutral from Buy at Janney).

Оригинал статьи: Ближайший уровень поддержки по SPY – 196.00 уровень сопротивления – 196.50



AMGN смотрим на откат вниз

WHR продажа от 150

MHK покупка выше 140

MIDD покупка выше 88

HAR покупка выше 113

SVXY покупка выше 84

GILD смотрим на продажу, ГЭП на премаркете

TAP покупка выше 75

Gapping up/down: JCP +2% after earnings, MNST +20% on KO strategic partnership, ACHN +17% after Phase 2 data; JD and JWN -4% after earnings; ICPT -2% after initiation with Underperf

Gapping up
In reaction to strong earnings/guidance: DQ +10.8%, VRML +10.7%, RIOM +9.5%, CEP +7.9%, LIME +7.6%, YOD +7.5%, SKBI +5.6%, WYY +5.4%, SINA +5.2%, ADSK +4.4%, HTM +4.3%, AMAT +3.8%, XON +3.6%, AGRX +2.7%, ROX +2.7%, CHL +2.7%, UPIP +2.5%, LEI +2%, JCP +2%, KITE +1.7%, MNDL +1.4%, AEG +1.2%, SAND +1%, EL +0.8%, A +0.7%.

M&A news: MNST +20.3% (Monster Beverage and Coca-Cola enter into long-term strategic partnership), KO +1.8% (Monster Beverage and Coca-Cola enter into long-term strategic partnership).

Other news: ACHN +17.5% (achieves 100% sustained virologic response rate from an eight week Phase 2 trial evaluating a ribavirin-free regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV), CRMD +8.2% (FDA accepted co's pivotal Phase 3 study protocol), FRO +4.3% (cont strength), SODA +3.7% (following MNST / KO ), GCI +2.3% (Icahn disclosed 6.63% active stake in 13D filing; supports split of the company), BHP +2.2% (announced update on portfolio; demerger of a selection of assets is co's preferred option), GLF +2% (to replace QCOR in the S&P SmallCap 600), DNOW +1.9% (new Berkshire Hathaway stake), PARR +1.9% (announced successful completion of common stock rights offering and award of $164 mln contract with Defense Logistics Agency Energy), MNK +1.9% (completes acquisition of Questcor (QCOR)), GILD +1.5% (disclosed favorable ruling in Roche (RHHBY) / Pharmasset case), CHTR +1% (new Berkshire Hathaway stake), EBAY +0.5% (may soon accept bitcoins at its payment unit, according to reports).

Analyst comments: CHL +2.7% (upgraded to Neutral from Underperform at Mizuho), UPL +1.8% (upgraded to Buy from Neutral at UBS ), GSJK +1.5% (upgraded to Overweight from Neutral at JP Morgan), MBI +1.2% (upgraded to Buy from Neutral at BTIG Research ), NXPI +0.8% (initiated with a Buy at Stifel)

Gapping down
In reaction to disappointing earnings/guidance: ICLD -9%, OPXA -7.8%, PIH -5.7%, PCTY -4.6%, JD -4.4%, JWN -4%, XGTI -3.9%, WB -3.1%, EXTR -1.9%.

Other news: NQ -15.8% ( announces management changes; CFO has resigned from his position for family reasons effective Aug 22, 2014), IDCC -6.7% (co announced it is disappointed with decision by the U.S. International Trade Commission to terminate Investigation No. 337-TA-868), NWBO -5.1% (announced pricing of $17.5 mln offering of convertible notes; convertible at $7.30/share; will fund new manufacturing capacity in Europe), CNAT -3.3% ( filed for a $150 mln mixed securities shelf offering), NEO -2.7% (announced public offering of common stock; size not disclosed), MASI -1.7% (disclosed it received a warning letter from the U.S. FDA regarding compliance with current Good Manufacturing Practices at Masimo's Irvine, CA manufacturing facility.), ZGNX -1.5% (disclosed it received a paragraph IV certification from Actavis (ACT) advising of the filing of an ANDA for a generic version of Zohydro).

Analyst comments: ICPT -2.1% (initiated with a Underperform at FBR Capital; tgt $172 ), KKR -1% (downgraded to Market Perform from Outperform at Wells Fargo), BEBE -0.7% (downgraded to Neutral from Buy at Janney).